NASDAQ:FDMT 4D Molecular Therapeutics Q3 2025 Earnings Results & Report $12.46 -0.02 (-0.16%) Closing price 11/10/2026 04:00 PM EasternExtended Trading$12.43 -0.03 (-0.24%) As of 11/10/2026 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. 4D Molecular Therapeutics beat analyst earnings expectations but missed on revenue in its Q3 2025 results, released November 10, 2025. The company reported EPS of -$1.01 versus the -$1.02 consensus estimate, while revenue of $90 thousand fell short of the $403 thousand estimate by $313.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 10, 2025TimeBefore Market OpensConference Call8:00 AM ET 4D Molecular Therapeutics EPS ResultsActual EPS-$1.01Consensus EPS -$1.02Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate3 of last 8 quarters4D Molecular Therapeutics Revenue ResultsActual Revenue$90 thousandExpected Revenue$403 thousandBeat/MissMissed by -$313.00 thousandYoY Revenue GrowthN/AUpcoming Earnings4D Molecular Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 16, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) 4D Molecular Therapeutics Q3 2025 Earnings FAQ Did 4D Molecular Therapeutics beat earnings estimates for Q3 2025? 4D Molecular Therapeutics (NASDAQ:FDMT) reported earnings of -$1.01 per share for Q3 2025, beating the consensus estimate of -$1.02. The report was announced on Monday, November 10, 2025. What was 4D Molecular Therapeutics' revenue for Q3 2025? 4D Molecular Therapeutics reported revenue of $90 thousand for Q3 2025, against a consensus estimate of $403 thousand. When is 4D Molecular Therapeutics' next earnings date? 4D Molecular Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for 4D Molecular Therapeutics on the company's earnings history page. 4D Molecular Therapeutics Earnings Headlines4D Molecular Therapeutics (FDMT) Projected to Post Quarterly Earnings on TuesdayNovember 9 at 2:10 AM | americanbankingnews.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Average Target Price of $30.22November 7, 2026 | americanbankingnews.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th. | Behind the Markets (Ad)4DMT to Participate in Upcoming Investor ConferencesNovember 3, 2026 | globenewswire.comContrasting Protalix BioTherapeutics (NYSE:PLX) & 4D Molecular Therapeutics (NASDAQ:FDMT)November 1, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and 4D Molecular Therapeutics (FDMT)October 21, 2026 | theglobeandmail.comSee More 4D Molecular Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 4D Molecular Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 4D Molecular Therapeutics and other key companies, straight to your email. Email Address About 4D Molecular Therapeutics4D Molecular Therapeutics (NASDAQ:FDMT) is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells. The company’s proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease. Founded in 2013, 4D Molecular Therapeutics is based in Emeryville, California. Its work is focused on developing gene therapies, rather than marketing approved medicines.View 4D Molecular Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity Upcoming Earnings Franco-Nevada (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
